Harbour Investments’s KalVista Pharmaceuticals KALV Stock Holding History

Harbour Investments’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1	Closed	–	–	3186
2021 Q3	$0	Buy	+1	New	+$20	﹤0.01%	3858

Other funds holding KALV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Harbour Investments's KALV Position: Q4 2021 in Review

Harbour Investments sold out of KalVista Pharmaceuticals (KALV) in Q4 2021, closing a stake of 1 share.

Harbour Investments first reported a position in KALV in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 97 funds tracked by Wall St. Rank hold KALV as of Q4 2021.

Harbour Investments reported no remaining KalVista Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Harbour Investments sold 1 KalVista Pharmaceuticals share in Q4 2021.
Harbour Investments first reported a position in KalVista Pharmaceuticals in Q3 2021 and held it in 1 quarter.
Harbour Investments's KalVista Pharmaceuticals position peaked at $0 in Q3 2021.
97 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2021.

Based on Harbour Investments's 13F filing for Q4 2021, filed 16 Feb 2022.